<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718740</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-Ⅰ-120</org_study_id>
    <nct_id>NCT04718740</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase I, Multi-center Study to Determine the Effect of Fluzoparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, Repaglinide and Bupropion in Patients With Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine,&#xD;
      S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent&#xD;
      ovarian cancer.&#xD;
&#xD;
      Secondary objective: To evaluate the safety of single dose of fluzoparib, caffeine,&#xD;
      S-warfarin, omeprazole, midazolam, repaglinide and bupropion or fluzoparib in combination&#xD;
      with caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with&#xD;
      recurrent ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion</measure>
    <time_frame>DAY1, DAY22</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion</measure>
    <time_frame>DAY1, DAY22</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of caffeine, S-warfarin, omeprazole, midazolam, repaglinide, bupropion and hydroxybupropion</measure>
    <time_frame>DAY1,DAY 22</time_frame>
    <description>Half life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Safety: Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination, vital signs, adverse events (NCI-CTC AE 5.0), etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>fluzoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: group A Intervention: Drug: fluzoparib, caffeine, vitamin K, warfarin, omeprazole, and midazolam&#xD;
Experimental: group B Intervention: Drug: fluzoparib, repaglinide and bupropion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluzoparib</intervention_name>
    <description>Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib</description>
    <arm_group_label>fluzoparib</arm_group_label>
    <other_name>caffeine, vitamin K, warfarin, omeprazole, midazolam, repaglinide and bupropion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to enter the study:&#xD;
&#xD;
          1. Patients are willing to participate this research and sign informed consent forms&#xD;
             (ICFs)&#xD;
&#xD;
          2. Patients must be ≥ 18 years of age at the date of signing the informed consent;&#xD;
&#xD;
          3. Patients with histologically diagnosed relapsed high grade (or middle and low&#xD;
             differentiation) serous ovarian cancer, fallopian tube cancer or primary peritoneal&#xD;
             cancer confirmed by pathology; ovarian endometrioid adenocarcinoma ≥ grade II; mixed&#xD;
             type tumor: high grade serous type or endometrioid component ≥ grade II should be more&#xD;
             than 50%;&#xD;
&#xD;
          4. Patients with platinum sensitive recurrent ovarian cancer, fallopian tube cancer or&#xD;
             primary peritoneal cancer achieved complete or partial remission after platinum&#xD;
             containing chemotherapy (carboplatin and cisplatin only). Platinum sensitive defined&#xD;
             as having disease progression greater than 6 months after completion of their last&#xD;
             dose of platinum chemotherapy. Patient must have received, at least 4 cycles of a&#xD;
             platinum based chemotherapy regimen for the last chemotherapy course&#xD;
&#xD;
          5. ECOG Performance Status of 0-1&#xD;
&#xD;
          6. Patients must have a life expectancy of at least 3 months&#xD;
&#xD;
          7. Patients must have normal organ and bone marrow function measured prior to&#xD;
             administration of study treatment as defined below:&#xD;
&#xD;
             HB≥100g/L； ANC≥1.5×109/L； PLT≥100×109/L or 1x UN TBIL≤1.5×ULN； ALT和AST≤3×ULN；&#xD;
             Cr≤1.5×ULN； Albumin&gt;30g/L；&#xD;
&#xD;
          8. Agree to abstain from sex or use effective non-drug contraceptives from screening to&#xD;
             at least 6 months after the last study drug administration (female subjects are also&#xD;
             required to abstain or use effective non-drug contraceptives two weeks prior to study&#xD;
             entry)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to enter the study:&#xD;
&#xD;
          1. Patients are willing to participate this research and sign informed consent forms&#xD;
             (ICFs)&#xD;
&#xD;
          2. Patients must be ≥ 18 years of age at the date of signing the informed consent;&#xD;
&#xD;
          3. Patients with histologically diagnosed relapsed high grade (or middle and low&#xD;
             differentiation) serous ovarian cancer, fallopian tube cancer or primary peritoneal&#xD;
             cancer confirmed by pathology; ovarian endometrioid adenocarcinoma ≥ grade II; mixed&#xD;
             type tumor: high grade serous type or endometrioid component ≥ grade II should be more&#xD;
             than 50%;&#xD;
&#xD;
          4. Patients with platinum sensitive recurrent ovarian cancer, fallopian tube cancer or&#xD;
             primary peritoneal cancer achieved complete or partial remission after platinum&#xD;
             containing chemotherapy (carboplatin and cisplatin only). Platinum sensitive defined&#xD;
             as having disease progression greater than 6 months after completion of their last&#xD;
             dose of platinum chemotherapy. Patient must have received, at least 4 cycles of a&#xD;
             platinum based chemotherapy regimen for the last chemotherapy course&#xD;
&#xD;
          5. ECOG Performance Status of 0-1&#xD;
&#xD;
          6. Patients must have a life expectancy of at least 3 months&#xD;
&#xD;
          7. Patients must have normal organ and bone marrow function measured prior to&#xD;
             administration of study treatment as defined below:&#xD;
&#xD;
             HB≥100g/L； ANC≥1.5×109/L； PLT≥100×109/L or 1x UN TBIL≤1.5×ULN； ALT和AST≤3×ULN；&#xD;
             Cr≤1.5×ULN； Albumin&gt;30g/L；&#xD;
&#xD;
          8. Agree to abstain from sex or use effective non-drug contraceptives from screening to&#xD;
             at least 6 months after the last study drug administration (female subjects are also&#xD;
             required to abstain or use effective non-drug contraceptives two weeks prior to study&#xD;
             entry)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who do meet any of the following criteria will not be allowed to enter the study:&#xD;
&#xD;
          1. Patients with previously (within 5 years) or at the same time with other incurable&#xD;
             malignant tumors, except for cured skin basal cell carcinoma, cervical carcinoma in&#xD;
             situ and breast cancer with no recurrence for more than 5 years after radical&#xD;
             operation&#xD;
&#xD;
          2. 3 months prior treatment with any poly adenosine diphosphate ribose polymerase&#xD;
             inhibitor (PARPi)&#xD;
&#xD;
          3. Patients with central nervous system metastasis&#xD;
&#xD;
          4. Serous cavity effusion (including pleural effusion, ascites and pericardial effusion)&#xD;
             with clinical symptoms and requiring symptomatic treatment; note: Patients with&#xD;
             symptomatic serous cavity effusion can be included in the group if there is no&#xD;
             disease, patients with symptomatic serous cavity effusion can be included in the group&#xD;
             if they are treated with symptomatic treatment (anti-cancer drugs can not be used for&#xD;
             serous cavity effusion treatment), and patients can be included in the group if judged&#xD;
             by researchers&#xD;
&#xD;
          5. Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any&#xD;
             gastrointestinal disorder or defect that would interfere with absorption of study&#xD;
             drugs&#xD;
&#xD;
          6. There are clinical cardiac symptoms or diseases that can not be well controlled, such&#xD;
             as: (1) NYHA grade 2 or above cardiac insufficiency, (2) unstable angina pectoris, (3)&#xD;
             acute myocardial infarction within one year, (4) clinically significant&#xD;
             supraventricular or ventricular arrhythmia requiring treatment or intervention, (5)&#xD;
             QTc &gt; 470ms&#xD;
&#xD;
          7. Patients with abnormal coagulation function (INR &gt; 1.5 or PT &gt; ULN + 4 seconds),&#xD;
             bleeding tendency or receiving thrombolytic or anticoagulant therapy&#xD;
&#xD;
          8. Contraindications of midazolam (allergic to benzodiazepine, myasthenia gravis,&#xD;
             schizophrenia, severe depression patients)&#xD;
&#xD;
          9. Warfarin contraindications (liver and kidney dysfunction, severe hypertension,&#xD;
             coagulation dysfunction with bleeding tendency, active ulcer, trauma, threatened&#xD;
             abortion, recent surgery)&#xD;
&#xD;
         10. Patients with contraindications to repaglinide and bupropion (patients with type I&#xD;
             diabetes, including insulin-dependent IDDM and C-peptide negative diabetes, diabetic&#xD;
             ketoacidosis with or without coma, patients with anorexia nervosa or bulimia, patients&#xD;
             with a history of severe epilepsy; patients with sudden abstinence or withdrawal of&#xD;
             sedatives); patients with diabetes other than the above Abnormal control&#xD;
&#xD;
         11. Not recovered from the previous adverse events before the first medication (previous&#xD;
             treatment adverse events, excluding hair loss and fatigue, recovered to ≤ 1 level)&#xD;
&#xD;
         12. Other clinical trial drugs were taken within 4 weeks before the first medication;&#xD;
&#xD;
         13. CYP1A2, CYP3A4, CYP2C9, CYP2C19 inducers or CYP1A2, CYP3A4, CYP2C9 and CYP2C19&#xD;
             inhibitors or P-gp inhibitors were taken within 4 weeks before the first medication&#xD;
             (for group A); CYP3A4, cyp2c8 and CYP2B6 inducers were taken within 4 weeks before the&#xD;
             first medication or CYP3A4, cyp2c8 and CYP2B6 inhibitors or transporter OATP1B1 were&#xD;
             taken within 2 weeks (or 5 half lives)/ P-gp inhibitor (for group B)&#xD;
&#xD;
         14. Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy,&#xD;
             gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs within&#xD;
             14 days prior to day 1&#xD;
&#xD;
         15. Alcoholics within 3 months before the first medication (drinking 14 units of alcohol&#xD;
             per week: 1 unit = 285 ml of beer, or 25 ml of spirits, or 100 ml of wine), and&#xD;
             smokers within 3 months before the first medication (smoking ≥ 5 cigarettes per day);&#xD;
&#xD;
         16. Ingestion of grapefruit or grapefruit products within 7 days before the first&#xD;
             medication, or ingestion of food or drink containing caffeine, xanthine or alcohol&#xD;
             within 72 hours before the first medication; strenuous exercise within 4 days before&#xD;
             the first medication; or other factors affecting drug absorption, distribution,&#xD;
             metabolism and excretion&#xD;
&#xD;
         17. Patients with history of immunodeficiency, including HIV positive, other acquired or&#xD;
             congenital immunodeficiency diseases, or organ transplantation&#xD;
&#xD;
         18. Syphilis infection or active hepatitis (hepatitis B reference: HBsAg positive and HBV&#xD;
             DNA ≥ 500 IU / ml; hepatitis C reference: HCV antibody positive and HCV copy number &gt;&#xD;
             upper limit of normal value)&#xD;
&#xD;
         19. Patients with active infections requiring antimicrobial therapy (e.g. antibiotics,&#xD;
             antiviral drugs, antifungal drugs);&#xD;
&#xD;
         20. According to the judgment of the researchers, there are concomitant diseases (serious&#xD;
             diabetes, thyroid diseases, etc.) that seriously endanger the safety of patients or&#xD;
             affect the completion of the study&#xD;
&#xD;
         21. Patients with history of drug allergy, or allergic to apatinib or ingredients&#xD;
&#xD;
         22. The researcher judges other situations that may affect the clinical research and the&#xD;
             judgment of research results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Wang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospitol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuya Wang, Ph.D.</last_name>
    <phone>13918749176</phone>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

